Trial reportBritish journal of pharmacology2001
A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine.
Trial report in British journal of pharmacology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 76 citations in OpenAlex.
- Mosquito salivary sialokinin reduces monocyte activation and chikungunya virus-induced inflammation via neurokinin receptors.Nature communications · 2025Article
- Isolation, Structure Elucidation, and Biological Activity of the Selective TACR2 Antagonist Tumonolide and its Aldehyde from a Marine Cyanobacterium.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024Article
- Recent Developments in On-Demand Voiding Therapies.The Journal of pharmacology and experimental therapeutics · 2024Review
- [LysJournal of basic and clinical physiology and pharmacology · 2023Article
- Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance.Cancers · 2022Review
- Chronic, Twice-Daily Dosing of an NK2 Receptor Agonist [LysJournal of neurotrauma · 2020Article
- Prokinetic effects of the neurokinin NK2 receptor agonist [LysNeuropeptides · 2019Article
- Colorectal and cardiovascular effects of [LysNaunyn-Schmiedeberg's archives of pharmacology · 2018Article
- NK2 and NK1 receptor-mediated effects of NKA and analogs on colon, bladder, and arterial pressure in anesthetized dogs.Naunyn-Schmiedeberg's archives of pharmacology · 2018Article
- Prokinetic effects of neurokinin-2 receptor agonists on the bladder and rectum of rats with acute spinal cord transection.European journal of pharmacology · 2018Article
- Pharmacodynamic evaluation of LysNaunyn-Schmiedeberg's archives of pharmacology · 2017Article
- An Endogenous Tachykinergic NK2/NK3 Receptor Cascade System Controlling the Release of Serotonin from Colonic Mucosa.Current neuropharmacology · 2015Review
- Review article: new receptor targets for medical therapy in irritable bowel syndrome.Alimentary pharmacology & therapeutics · 2010Review
- Current and novel therapeutic options for irritable bowel syndrome management.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2009Review
- Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome.Therapeutic advances in gastroenterology · 2009Article
- Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Gastroenterology · 2008Review
- Updates on treatment of irritable bowel syndrome.World journal of gastroenterology · 2008Review
- Irritable bowel syndrome: update on colonic neuromuscular dysfunction and treatment.Current gastroenterology reports · 2006Review
- Review
- Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome.British journal of pharmacology · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. MEN 11420 (nepadutant) is a potent, selective and competitive antagonist of tachykinin NK2 receptors. 2. The objective of the present study was to assess the capability of the drug to antagonize the stimulatory effects of neurokinin A (NKA) on gastrointestinal motility, as well as to change the fasting migrating motor complex (MMC). 3. Thirty-four male volunteers were randomized to treatment with either placebo or MEN 11420 in a double-blinded manner. Effects of MEN 11420 (8 mg intravenously) were evaluated as changes in phases I, II and III of MMC, as well as contraction frequency, amplitude and motility index during baseline conditions and during stimulation of motility using NKA (25 pmol kg(-1) min(-1) intravenously). 4. NKA preceded by placebo increased the fraction of time occupied by phase II, increased contraction frequency, amplitude and motility index. 5. MEN 11420 effectively antagonized the motility-stimulating effects of NKA. MEN 11420 reduced the phase II-stimulating effect of NKA. In addition, the stimulatory effect of NKA on contraction frequency and amplitude, as well as motility index were inhibited by MEN 11420. MEN 11420 did not affect the characteristics of MMC during saline infusion. 6. Plasma levels of MEN 11420 peaked during the first hour after infusion and decreased to less than half during the first 2 h. 7. In conclusion, intravenous MEN 11420 effectively inhibited NKA-stimulated, but not basal gastrointestinal motility, and was well tolerated by all subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.